Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00013559 · ClinicalTrials.gov registry record

Natural History Study of Smith-Magenis Syndrome

A clinical trial of Smith-Magenis Syndrome (SMS), sponsored by National Human Genome Research Institute (NHGRI).

Active
Registry status
593
Enrollment target
1
Study location

NCT00013559: Active study of Smith-Magenis Syndrome (SMS), sponsored by National Human Genome Research Institute (NHGRI).

NCT00013559 is a study of Smith-Magenis Syndrome (SMS) that is active but no longer recruiting, run by National Human Genome Research Institute (NHGRI). The registered enrollment target is 593 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00013559, a study of Smith-Magenis Syndrome (SMS), is active but no longer recruiting, sponsored by National Human Genome Research Institute (NHGRI).

ACTIVE NOT RECRUITING
Registry status
593 participants
Enrollment target
1
Study location

Study Summary

This study will examine how a rare disease called Smith-Magenis syndrome (SMS) affects people and how they change over time. SMS is caused by a small chromosome 17p11.2 deletion (missing piece). The syndrome is associated with distinct physical, developmental and behavioral characteristics, but it is not fully understood. To learn more about this disease, a multidisciplinary research team will study: * The range and type of medical, behavioral, and learning problems of people with SMS * The deletion of chromosome 17p11.2 to find the gene or genes that cause SMS * Whether certain specific genetic changes cause certain specific medical problems * What signs and symptoms must be present to make a diagnosis of SMS * The impact that a child with SMS has on his or her family members. Patients of all ages with SMS may be eligible for this study. They will be evaluated by a team of medical specialists at the NIH Clinical Center over the course of several days. Parents of patients will be asked to provide copies of past medical records and tests results for review. They will provide a family medical history and information on the child s prenatal, developmental, behavioral and medical histories. The study may involve the following evaluations: physical, neurological and psychological exams; ear, nose and throat evaluation; speech, language and swallowing evaluation; hearing test; eye examination; imaging studies (e.g., X-rays, ultrasound, MRI); developmental and behavioral assessment; rehabilitation evaluation with gait (walking) analysis; urinalysis, blood, and/or skin cell studies; sleep study; other consultations as required. A tissue sample (blood or cheek swab or skin biopsy) may be taken for genetic studies. To obtain a cheek swab, a small brush is rubbed against the inside of the cheek to wipe off some cells. For a skin biopsy, a small area of skin is numbed with a local anesthetic and a small circle of skin, usually about 1/8 inch, is removed with a biopsy tool. P

Primary Outcome

The major objective of this project is to investigate the clinical and molecular manifestations, phenotypic variability, natural history and pathogenesis of Smith-Magenis syndrome (SMS).

Study Locations (1)

Maryland

  • National Institutes of Health Clinical Center - Bethesda

Trial Details

FieldValue
Enrollment Target 593 participants
Start Date 2001-03-19

What the registry record for NCT00013559 still lists

NCT00013559 is an observational study that tracks outcomes without assigning an intervention. The registered 593 participants enrollment target is mid-sized for trials with a published cap.

The record links to 1 condition, with Smith-Magenis Syndrome (SMS) appearing as the primary indexed condition, and to 0 interventions.

NCT00013559 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT00013559 about?

NCT00013559 is a clinical study titled "Natural History Study of Smith-Magenis Syndrome". This study will examine how a rare disease called Smith-Magenis syndrome (SMS) affects people and how they change over time. SMS is caused by a small chromosome 17p11.2 deletion (missing piece). The syndrome is associated with distinct physical, developmental and behavioral characteristics, but it i...

What is the current status of trial NCT00013559?

This trial is currently active not recruiting. The enrollment target is 593 participants. The study started on 2001-03-19.

What conditions does trial NCT00013559 study?

This clinical trial studies the following conditions: Smith-Magenis Syndrome (SMS).

Who is sponsoring clinical trial NCT00013559?

This trial is sponsored by National Human Genome Research Institute (NHGRI), which has 185 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00013559 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04701684 · 594 participants · NA

    WE-TRUST (Workflow Optimization to Reduce Time to Endovascular Reperfusion for Ultra-fast Stroke Treatment)

  • NCT05491213 · 594 participants · NA

    TELESCOPE- TELEhealth Shared Decision-making COaching

  • NCT05867420 · 594 participants · Phase 1

    A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.

  • NCT06890884 · 594 participants · Phase 2

    A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT00013559, the US trial registry maintained by the National Library of Medicine. NCT00013559 (mid enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.